Trials / Completed
CompletedNCT00219154
A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazidebased Treatment Regimen With Optional Addition of Amlodipine
A Twenty Six-week, Randomized, Double-blind, Parallel Group, Multicenter, Active Controlled, Dose Titration Study to Evaluate the Efficacy and Safety of Aliskiren Compared to HCTZ With the Optional Addition of Amlodipine, Followed by a Second Twenty Six Weeks of Blinded Treatment, in Patients With Essential Hypertension
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,125 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to compare the long-term efficacy and safety of an aliskiren based regimen to an HCTZ based treatment regimen with optional addition of amlodipine in patients with essential hypertension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | aliskiren |
Timeline
- Start date
- 2005-03-01
- Primary completion
- 2006-01-01
- Completion
- 2006-01-01
- First posted
- 2005-09-22
- Last updated
- 2011-11-08
Locations
2 sites across 2 countries: Germany, Switzerland
Source: ClinicalTrials.gov record NCT00219154. Inclusion in this directory is not an endorsement.